XIX International AIDS Conference


FRLBX Late Breaker Cross-Track
  Oral Abstract Session : Cross-Track
Venue: Session Room 7
Time: 27.07.2012, 11:00 - 12:30
Co-Chairs: Adaora Adimora, United States
Sten H Vermund, United States
 
 

11:00
FRLBX01
Abstract
HIV prevalence trends after scale-up of antiretroviral treatment: a population-based study in a poor rural community in KwaZulu-Natal
J. Zaidi1, E. Grapsa1, F. Tanser1, M.-L. Newell1,2, T. Bärnighausen1,3
1Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Mtubatuba, South Africa, 2MRC Centre for Epidemiology of Child Health, University College London Institute of Child Health, London, United Kingdom, 3Harvard School of Public Health, Global Health and Population, Boston, United States
J. Zaidi, South Africa

11:13
FRLBX02
Abstract
Powerpoint
Webcast
Estimating national HIV incidence from directly observed seroconversions in the Swaziland HIV Incidence Measurement Survey (SHIMS) longitudinal cohort
J.B. Reed1, J. Justman2, G. Bicego3, D. Donnell4, N. Bock1, H. Ginindza5, A. Koler2, N. Philip2, M. Makhanya3, C. Mlambo6, B.S. Parekh1, Y.T. Duong1, D.L. Ellenberger1, C. Sexton1, R. Nkambule5
1U.S. Centers for Disease Control and Prevention, Center for Global Health, Division of Global HIV/AIDS, Atlanta, United States, 2ICAP at the Mailman School of Public Health at Columbia University, New York, United States, 3US Centers for Disease Control and Prevention, Swaziland, Mbabane, Swaziland, 4Fred Hutchinson Cancer Research Center, Seattle, United States, 5Ministry of Health - Swaziland, Mbabane, Swaziland, 6Columbia University, ICAP, Swaziland, Mbabane, Swaziland
J. Reed, United States

11:26
FRLBX03
Abstract
Powerpoint
Webcast
HIV prevalence, sexual risks and HIV knowledge among men who have sex with men (MSM) in Malawi: understanding risks among a stigmatized population and opportunities for interventions
A. Wirtz1, G. Trapence2, V. Jumbe3, E. Umar3, S. Ketende1, D. Kamba2, M. Berry1,4, S. Stromdahl1,5, C. Beyrer1, S. Baral1
1Johns Hopkins Bloomberg School of Public Health, Epidemiology, Baltimore, United States, 2Center for the Development of People, Blantyre, Malawi, 3Malawi College of Medicine, Blantyre, Malawi, 4Johns Hopkins Bloomberg School of Public Health, International Health, Baltimore, United States, 5Karolinska Institutet, Public Health Sciences, Stockholm, Sweden
A. Wirtz, United States

11:39
FRLBX04
Abstract
Pre-exposure prophylaxis (PrEP) will have a limited impact on the prevalence of HIV-1 drug resistance in sub-Saharan Africa: comparison of mathematical models
D. van de Vijver1, B. Nichols1, U. Abbas2, V. Cambiano3, J. Eaton4, R. Glaubius5, K. Lythgoe4, J. Mellors6, A. Phillips3, K. Sigaloff7,8, T. Hallett4
1Erasmus Medical Centre, Virology, Rotterdam, Netherlands, 2Cleveland Clinic Foundation, Infectious Diseases, Cleveland, United States, 3University College London, Infection and Population Health, London, United Kingdom, 4Imperial College, Infectious Disease Epidemiology, London, United Kingdom, 5Cleveland Clinic Foundation, Infection and Population Health, Cleveland, United States, 6University of Pittsburgh School of Medicine, Infectious Diseases, Pittsburgh, United States, 7PharmAccess Foundation, Amsterdam, Netherlands, 8Amsterdam Institute for Global Health and Development (AIGHD), Amsterdam, Netherlands
B. Nichols, Netherlands

11:52
FRLBX05
Abstract
Continuum of HIV care: differences in care and treatment by sex and race/ethnicity in the United States
H.I. Hall1, E.L. Frazier1, P. Rhodes1, D.R. Holtgrave2, C. Furlow-Parmley1, T. Tang3, K.M. Gray1, S.M. Cohen1, J. Skarbinski1
1Centers for Disease Control and Prevention, Atlanta, United States, 2Johns Hopkins Bloomberg School of Public Health, Baltimore, United States, 3ICF International, Atlanta, United States
H. Hall, United States

12:05
FRLBX06
Abstract
Powerpoint
Webcast
The clinical and economic impact of a generic first-line antiretroviral regimen in the U.S.
R.P. Walensky1, P.E. Sax2, Y.M. Nakamura3, M.C. Weinstein4, P.P. Pei3, K.A. Freedberg1, A.D. Paltiel5, B.R. Schackman6
1Massachusetts General Hospital, Harvard Medical School, Boston, United States, 2Brigham and Women's Hospital, Harvard Medical School, Boston, United States, 3Massachusetts General Hospital, Boston, United States, 4Harvard School of Public Health, Boston, United States, 5Yale School of Medicine, New Haven, United States, 6Weill Cornell Medical College, New York, United States
R. Walensky, United States

Powerpoints presentations
Estimating national HIV incidence from directly observed seroconversions in the Swaziland HIV Incidence Measurement Survey (SHIMS) longitudinal cohort - Jason Bailey Reed

HIV prevalence, sexual risks and HIV knowledge among men who have sex with men (MSM) in Malawi: understanding risks among a stigmatized population and opportunities for interventions - Andrea Wirtz

The clinical and economic impact of a generic first-line antiretroviral regimen in the U.S. - Rochelle P. Walensky



   

    The organizers reserve the right to amend the programme.


Contact Us | Site map © 2012 International AIDS Society